Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
10 studies found for:    "Autoimmune lymphoproliferative syndrome"
Show Display Options
RSS Create an RSS feed from your search for:
"Autoimmune lymphoproliferative syndrome"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Withdrawn Fluorodeoxyglucose Imaging Studies to Detect Lymphoma
Conditions: Autoimmune Lymphoproliferative Syndrome;   Lymphoma
Intervention:
2 Recruiting Study of Autoimmune Lymphoproliferative Syndrome (ALPS)
Condition: Autoimmune Lymphproliferative Syndrome
Intervention:
3 Completed
Has Results
Valproic Acid (Depakote[Registered Trademark]) to Treat Autoimmune Lymphoproliferative Syndrome (ALPS)
Conditions: ALPS;   Hypersplenism;   Lymphadenopathy
Interventions: Drug: Valproic Acid;   Procedure: CT Scan;   Procedure: Blood Sample
4 Completed Pyrimethamine and Sulfadoxine for Treatment of Autoimmune Lymphoproliferative Syndrome
Conditions: Autoimmune Disease;   Lymphoproliferative Disorder
Intervention: Drug: Fansidar (pyrimethamine and sulfadoxine)
5 Completed Pyrimethamine to Treat Autoimmune Lymphoproliferative Syndrome
Conditions: Autoimmune Disease;   Lymphatic Disease;   Lymphoproliferative Disorder
Intervention: Drug: Pyrimethamine
6 Completed Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) to Evaluate Autoimmune Lymphoproliferative Syndrome (ALPS) and ALPS-associated Lymphoma
Conditions: Lymphoproliferative Disorders;   Lymphoma
Intervention:
7 Recruiting Immune Disorder HSCT Protocol
Conditions: Immune Deficiency Disorders;   Severe Combined Immunodeficiency;   Chronic Granulomatous Disease;   X-linked Agammaglobulinemia;   Wiskott-Aldrich Syndrome;   Hyper-IgM;   DiGeorge Syndrome;   Chediak-Higashi Syndrome;   Common Variable Immune Deficiency;   Immune Dysregulatory Disorders;   Hemophagocytic Lymphohistiocytosis;   IPEX;   Autoimmune Lymphoproliferative Syndrome;   X-linked Lymphoproliferative Syndrome
Intervention: Drug: Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan
8 Active, not recruiting Sirolimus for Autoimmune Disease of Blood Cells
Conditions: Autoimmune Pancytopenia;   Autoimmune Lymphoproliferative Syndrome (ALPS);   Evans Syndrome;   Idiopathic Thrombocytopenic Purpura;   Anemia, Hemolytic, Autoimmune;   Autoimmune Neutropenia;   Lupus Erythematosus, Systemic;   Inflammatory Bowel Disease;   Rheumatoid Arthritis
Intervention: Drug: sirolimus
9 Enrolling by invitation Comparative Autoantibody and Immunologic Cell Marker Study
Conditions: Autoimmune Diseases;   Lupus Erythematosus, Systemic;   Communicable Diseases
Intervention:
10 Recruiting Reduced Intensity Conditioning in Patients Aged ≤35 With Non-Malignant Disorders Undergoing UCBT, BMT, or PBSCT
Conditions: Primary Immunodeficiency Syndromes;   Congenital Bone Marrow Failure Syndromes;   Inherited Metabolic Disorders (IMD);   Hereditary Anemias;   Patients With Sickle Disease Presenting Specific Symptoms
Interventions: Drug: Hydroxyurea;   Drug: Alemtuzumab;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Thiotepa

Study has passed its completion date and status has not been verified in more than two years.